Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

NCT02060266 · Completed

Last updated 2026-05-28

This clinical trial tests how a single injected dose of a labeled diabetes medication ([3H]-semaglutide) is absorbed, broken down, and removed from the body in healthy adult men.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 7 people

Who can join Ages 45–64 · male only Healthy volunteers accepted.

Timeline Started 2014-02 · est. completion 2014-04

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT02060266 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of the trial is to investigate the absorption, metabolism and excretion after a single subcutaneous dose of \[3H\]-semaglutide in healthy male subjects.

Treatments tested

semaglutide Drug

Subjects will receive a single dose subcutaneously (s.c., under the skin).

Main thing measured	Concentration of the major metabolites of [3H]-semaglutide in plasma, urine, and faeces
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02060266 ↗